LLY

726.38

-2.12%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

LLY

726.38

-2.12%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

LLY

726.38

-2.12%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

LLY

726.38

-2.12%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

LLY

726.38

-2.12%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

Search

Johnson and Johnson

Suletud

SektorTervishoid

178.17 -0.26

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

177.28

Max

178.29

Põhinäitajad

By Trading Economics

Sissetulek

-5.5B

5.5B

Müük

1.9B

24B

P/E

Sektori keskmine

18.969

35.733

Aktsiakasum

2.77

Dividenditootlus

2.86

Kasumimarginaal

23.321

Töötajad

138,100

EBITDA

-9.1B

6.5B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+0.73% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.86%

3.13%

Järgmine tulemuste avaldamine

14. okt 2025

Järgmine dividendimakse kuupäev

9. sept 2025

Järgmine aktsia dividendi kuupäev (ex-date)

25. nov 2025

Turustatistika

By TradingEconomics

Turukapital

49B

427B

Eelmine avamishind

178.43

Eelmine sulgemishind

178.17

Uudiste sentiment

By Acuity

20%

80%

108 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Johnson and Johnson Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. juuli 2025, 16:47 UTC

Tulu

J&J Raises Full-Year Outlook After Beating 2Q Expectations -- Update

29. aug 2025, 20:24 UTC

Tulu

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

16. juuli 2025, 18:08 UTC

Market Talk
Tulu

J&J's Orthopedic Decline Likely Hinges on Company-Specific Challenges -- Market Talk

16. juuli 2025, 17:27 UTC

Market Talk
Tulu

J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

16. juuli 2025, 17:17 UTC

Market Talk
Tulu

J&J Sees Growth Across Portfolio Offsetting Loss of Stelara -- Market Talk

16. juuli 2025, 16:34 UTC

Market Talk
Tulu

J&J Sees Lower Tariff Risk for the Year -- Market Talk

16. juuli 2025, 13:27 UTC

Tulu

Johnson & Johnson Beats Earnings Estimates. CFO Says It Can Do Any Deal It Wants. -- Barrons.com

16. juuli 2025, 10:32 UTC

Tulu

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16. juuli 2025, 10:22 UTC

Tulu

Correct: Johnson & Johnson 2Q International Sales $10.2B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.63-$10.73 Vs Prior Outlook $10.50-$10.70 >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson Raises 2025 View To Sales $93.2B-$93.6B Vs Prior Outlook $91B-$91.8B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson Raises 2025 View To Adj EPS $10.80-Adj EPS $10.90 Vs Prior Outlook $10.50-$10.70 >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.5%-5% Vs Prior Range 3.3%-4.3% >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson Now Sees 2025 Operational Sales of $92.7B-$93.1B Vs Prior Outlook $91.6B-$92.4B>JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson: Our Portfolio and Pipeline Position Us for Elevated Growth in Second Half of Year >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.2%-3.7% Vs Prior Outlook 2%-3% >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson: 2Q MedTech Business Delivered Operational Sales Growth of 6.1%, Driven Primarily by Strength in Electrophysiology Products and Abiomed, Wound Closure Pdts and Improved Performance in Surgical Vision >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q Worldwide MedTech Sales $8.54B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Rybrevant, Lazcluze, Tremfya and Spravato >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Grew 3.8% With 13 Brands Growing Double Digits >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q International Sales $23.74B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q U.S. Sales $13.54B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q Sales $23.74B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q EPS $2.29 >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q Adj EPS $2.77 >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q Orthopaedics Sales $2.3B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q Orthopaedics Sales $2.31B >JNJ

16. juuli 2025, 10:20 UTC

Tulu

Johnson & Johnson 2Q International Sales $10.2B >JNJ

Võrdlus sarnastega

Hinnamuutus

Johnson and Johnson Prognoos

Hinnasiht

By TipRanks

0.73% tõus

12 kuu keskmine prognoos

Keskmine 180.06 USD  0.73%

Kõrge 200 USD

Madal 165 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Johnson and Johnson 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

9

Osta

9

Hoia

0

Müü

Tehniline skoor

By Trading Central

154.93 / 155.895Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

108 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat